Abstract:Amantadine and modafinil are neurostimulants that may improve cognitive and functional recovery post-stroke, but the existing study results vary, and no comprehensive review has been published. This systematic review describes amantadine and modafinil administration practices post-stroke, evaluates timing and impact on clinical effectiveness measures, and identifies the incidence of potential adverse drug effects. A librarian-assisted search of the MEDLINE (PubMed) and EMBASE databases identified all English-language publications with "amantadine" or "modafinil" in the title or abstract from inception through February 1, 2020. Publications meeting predefined Patient, Intervention, Comparator, Outcome (PICO) criteria were included: Patients (≥ 18 years of age post-stroke); Intervention (amantadine or modafinil administration); Comparison (pretreatment baseline or control group); Outcomes (cognitive or functional outcome). Amantadine and modafinil administration practices, cognitive and functional outcomes, and incidence of potential adverse drug effects were collected following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidance. Quantitative analyses were not performed due to heterogeneity in the clinical effectiveness measures; descriptive data are presented as number (percent) or median (interquartile range). Of 12,620 publications initially identified, 10 amantadine publications (n = 121 patients) and 12 modafinil publications (n = 120 patients) were included. Amantadine was initiated 39 (16, 385) days post-stroke, with most common initial doses of 100 mg once or twice daily (range 100-200 mg/day), and final daily dose of 200 (188, 200) mg/day. Modafinil was initiated 170 (17, 496) days post-stroke, with initial and final daily doses of 100 (100, 350) mg/day and 200 (100, 350) mg/day, respectively. The most common indication was consciousness disorders for amantadine (n = 3/10 publications; 30%) and fatigue for modafinil (n = 5/12; 42%). Forty unique clinical effectiveness measures (1.8 per study) with 141 domains (6.4 per study) were described across all studies. A positive response in at least one clinical effectiveness measure was reported in 70% of amantadine publications and 83% of modafinil publications. Only one publication each for amantadine (10%; n = 5 patients) and modafinil (8%; n = 21 patients) studied acutely hospitalized or ICU patients; both were randomized studies showing improvements in neurocognitive function for amantadine and fatigue for modafinil. Potential adverse drug effects were reported in approximately 50% of publications, most commonly visual hallucinations with amantadine (2% of patients) and dizziness (5% of patients) and dry eyes or mouth (5% of patients). Amantadine and modafinil may improve cognitive and functional recovery post-stroke, but higher-quality data are needed to confirm this conclusion, especially in the acute care setting.

The Effects of Modafinil on Mood and Cognition in Huntington's Disease.

Cognitive Enhancing Effects of Modafinil in Healthy Volunteers

Modafinil Improves Cognition and Response Inhibition in Adult Attention-Deficit/hyperactivity Disorder.

Modafinil Improves Cognition and Attentional Set Shifting in Patients with Chronic Schizophrenia

Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers.

Effects Of Modafinil On Behavioral Learning And Hippocampal Synaptic Transmission In Rats

Effects of modafinil on attention performance, short-term memory and executive function in university students: a randomized trial

Effect of Modafinil on Learning and Task-Related Brain Activity in Methamphetamine-Dependent and Healthy Individuals

Effects of Modafinil and Prazosin on Cognitive and Physiological Functions in Healthy Volunteers.

Modafinil therapy and mental status following aneurysmal subarachnoid hemorrhage: comprehensive stroke-center analysis

Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects

Efficacy of Modafinil on Fatigue and Excessive Daytime Sleepiness Associated with Neurological Disorders: A Systematic Review and Meta-Analysis

Dose-dependent subacute cardiovascular effects of modafinil in rats

Combined Electrochemistry and Mass Spectrometry Imaging to Interrogate the Mechanism of Action of Modafinil, a Cognition-Enhancing Drug, at the Cellular and Sub-Cellular Level

Acute Regulation of the Arousal-Enhancing Drugs Caffeine and Modafinil on Class IIa HDACs In Vivo and In Vitro: Focus on HDAC7

Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic Review

Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy

Modafinil, an atypical CNS stimulant?

Modafinil: new indications for wake promotion

Modafinil Does Enhance Cognition, Review Finds

Modafinil protects hippocampal neurons by suppressing excessive autophagy and apoptosis in mice with sleep deprivation